Saturday, November 23, 2024
HomeBusinessWhat's Subsequent: Agilent Applied sciences's Earnings Preview - Agilent Applied sciences (NYSE:A)

What’s Subsequent: Agilent Applied sciences’s Earnings Preview – Agilent Applied sciences (NYSE:A)


Agilent Applied sciences A is making ready to launch its quarterly earnings on Monday, 2024-11-25. Here is a short overview of what buyers ought to take into account earlier than the announcement.

Analysts anticipate Agilent Applied sciences to report an earnings per share (EPS) of $1.40.

Buyers in Agilent Applied sciences are eagerly awaiting the corporate’s announcement, hoping for information of surpassing estimates and optimistic steering for the subsequent quarter.

It is price noting for brand new buyers that inventory costs will be closely influenced by future projections reasonably than simply previous efficiency.

Earnings Monitor File

Final quarter the corporate beat EPS by $0.06, which was adopted by a 0.16% improve within the share value the subsequent day.

Here is a take a look at Agilent Applied sciences’s previous efficiency and the ensuing value change:

Quarter Q3 2024 Q2 2024 Q1 2024 This fall 2023
EPS Estimate 1.26 1.19 1.22 1.35
EPS Precise 1.32 1.22 1.29 1.38
Value Change % 0.0% -10.0% 3.0% 9.0%

eps graph

Market Efficiency of Agilent Applied sciences’s Inventory

Shares of Agilent Applied sciences have been buying and selling at $132.06 as of November 21. Over the past 52-week interval, shares are up 5.86%. On condition that these returns are typically optimistic, long-term shareholders needs to be glad going into this earnings launch.

Analyst Observations about Agilent Applied sciences

Understanding market sentiments and expectations inside the business is essential for buyers. This evaluation delves into the newest insights on Agilent Applied sciences.

Analysts have offered Agilent Applied sciences with 3 scores, leading to a consensus score of Impartial. The typical one-year value goal stands at $149.0, suggesting a possible 12.83% upside.

Evaluating Rankings Amongst Business Friends

On this evaluation, we delve into the analyst scores and common 1-year value targets of IQVIA Hldgs, Waters and Illumina, three key business gamers, providing insights into their relative efficiency expectations and market positioning.

  • The prevailing sentiment amongst analysts is an Outperform trajectory for IQVIA Hldgs, with a median 1-year value goal of $261.21, implying a possible 97.8% upside.
  • The prevailing sentiment amongst analysts is an Impartial trajectory for Waters, with a median 1-year value goal of $370.0, implying a possible 180.18% upside.
  • For Illumina, analysts mission an Impartial trajectory, with a median 1-year value goal of $173.56, indicating a possible 31.43% upside.

Abstract of Friends Evaluation

The peer evaluation abstract supplies a snapshot of key metrics for IQVIA Hldgs, Waters and Illumina, illuminating their respective standings inside the business. These metrics provide priceless insights into their market positions and comparative efficiency.

Firm Consensus Income Progress Gross Revenue Return on Fairness
Agilent Applied sciences Impartial -5.62% $855M 4.65%
IQVIA Hldgs Outperform 4.28% $1.38B 4.17%
Waters Impartial 4.02% $438.65M 10.71%
Illumina Impartial -3.49% $745M 39.60%

Key Takeaway:

Agilent Applied sciences ranks within the center amongst friends for Consensus score. It’s on the backside for Income Progress. For Gross Revenue, it’s on the prime. When it comes to Return on Fairness, Agilent Applied sciences is on the backside in comparison with its friends.

Delving into Agilent Applied sciences’s Background

Initially spun out of Hewlett-Packard in 1999, Agilent has advanced into a number one life science and diagnostic agency. At the moment, Agilent’s measurement applied sciences serve a broad base of shoppers with its three working segments: life science and utilized instruments, cross lab consisting of consumables and providers associated to life science and utilized instruments, and diagnostics and genomics. Over half of its gross sales are generated from the biopharmaceutical, chemical, and superior supplies finish markets, which we view because the stickiest finish markets, nevertheless it additionally helps scientific lab, environmental, forensics, meals, tutorial, and government-related organizations. The corporate is geographically numerous, with operations within the US and China representing the biggest nation concentrations.

Agilent Applied sciences: A Monetary Overview

Market Capitalization: Positioned above business common, the corporate’s market capitalization underscores its superiority in measurement, indicative of a robust market presence.

Income Progress: Agilent Applied sciences’s income progress over a interval of three months has confronted challenges. As of 31 July, 2024, the corporate skilled a income decline of roughly -5.62%. This means a lower within the firm’s top-line earnings. As in comparison with rivals, the corporate encountered difficulties, with a progress price decrease than the typical amongst friends within the Well being Care sector.

Internet Margin: Agilent Applied sciences’s internet margin excels past business benchmarks, reaching 17.87%. This signifies environment friendly price administration and powerful monetary well being.

Return on Fairness (ROE): Agilent Applied sciences’s ROE stands out, surpassing business averages. With a powerful ROE of 4.65%, the corporate demonstrates efficient use of fairness capital and powerful monetary efficiency.

Return on Belongings (ROA): Agilent Applied sciences’s monetary power is mirrored in its distinctive ROA, which exceeds business averages. With a outstanding ROA of 2.58%, the corporate showcases environment friendly use of belongings and powerful monetary well being.

Debt Administration: With a below-average debt-to-equity ratio of 0.5, Agilent Applied sciences adopts a prudent monetary technique, indicating a balanced method to debt administration.

To trace all earnings releases for Agilent Applied sciences go to their earnings calendar on our web site.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.

© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments